Beyond the “Overdiagnosis” Narrative: Understanding Adult ADHD Through DSM-5

Why It Matters

Understanding the true causes of the stimulant shortage informs policy and clinical practice, ensuring patients receive needed treatment without unnecessary restrictions.

Key Takeaways

• DSM‑5 expanded adult ADHD criteria, reflecting underdiagnosed population.
• Clinician training deficits drive misuse of brief diagnostic tools.
• DEA quota restrictions, not overdiagnosis, fuel stimulant shortage.
• Self‑report scales remain essential for functional impairment assessment.
• Extensive neuropsych testing impractical for primary‑care settings.

Pulse Analysis

The DSM‑5 marked a paradigm shift by recognizing ADHD as a lifelong neurobiological condition, not merely a childhood disorder. By lowering the symptom threshold for adults and tailoring language to mature presentations, the manual opened the door for millions of previously missed diagnoses. This reclassification aligns with epidemiological data showing that adult ADHD prevalence has long been underestimated, and it validates the experiences of patients who have struggled without proper recognition.

In practice, however, the promise of broader diagnostic criteria collides with real‑world constraints. Primary‑care physicians often receive minimal training in ADHD assessment and are pressured to complete evaluations within brief visits. Consequently, many rely on checklist‑style DSM‑5 criteria or short self‑report scales, which, while useful, cannot replace the depth of a two‑hour neuropsychological battery. The shortage of trained specialists and the impracticality of extensive testing contribute to both false‑positive and false‑negative outcomes, underscoring the need for scalable, evidence‑based diagnostic pathways that balance rigor with feasibility.

Beyond clinical challenges, the stimulant shortage is rooted in regulatory policy. The DEA’s Schedule II production quotas have remained static despite rising legitimate demand, creating a supply‑demand mismatch that exacerbates access issues. While recent quota increases aim to alleviate pressure, the underlying framework still prioritizes control over patient availability. Policymakers must recalibrate these limits, integrating data on adult ADHD prevalence and treatment necessity, to prevent future shortages while maintaining appropriate safeguards against diversion.